Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Macerata

31 clinical trials in Macerata, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Macerata at a glance
31
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

31 trials in Macerata

Open in trial search

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Metastatic renal cell carcinoma

Recruiting

Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Hormone-refractory prostate cancer

Recruiting

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Non-small cell lung cancer stage IV

Recruiting

Study Comparing Atezolizumab Alone and Atezolizumab with Bevacizumab for First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Ricerca Traslazionale

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Consorzio Oncotech

Prostate cancer

Recruiting

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Fondazione Radioterapia Oncologica Onlus

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Bladder transitional cell carcinoma

Not yet recruiting

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Transitional cell carcinoma metastatic

Not yet recruiting

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Macerata

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on triple-negative breast cancer and hormone receptor-positive breast cancer treatments, evaluating innovative therapeutic approaches including immunotherapy combinations and targeted therapies.

  • Advanced treatment sequencing studies
  • Novel drug combinations
  • Hormone therapy optimization

Research emphasizes personalized treatment strategies for different breast cancer subtypes.

02 Urological Oncology

Groundbreaking research in bladder cancer and prostate cancer, investigating new immunotherapy approaches and targeted treatments for both early-stage and advanced disease.

  • Non-muscle invasive bladder cancer therapies
  • Advanced prostate cancer treatments
  • Combination therapy approaches

Studies focus on improving patient outcomes through innovative treatment combinations.

03 Advanced Cancer Therapies

Investigating cutting-edge treatments for metastatic cancers, including studies on renal cell carcinoma and various other advanced malignancies.

  • Targeted therapy development
  • Immunotherapy optimization
  • Personalized treatment approaches

Research aims to improve survival rates and quality of life for patients with advanced disease.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.